October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 ...

The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen strong treatment advancements.

New results from Eli Lilly and Company and Incyte showed once-daily, oral baricitinib 4 mg helped the majority of adolescent ...